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aa = amino acids 
Aβ = Amyloid-β protein   
AD = Alzheimer’s disease 
ADAM = A Disintegrin And Metalloprotease 
AEP = asparagine endopeptidase  
AICD = APP intracellular domain  
Aph-1 = anterior pharynx-defective 1  
APP = amyloid precursor protein  
BDNF = brain-derived neurotrophic factor 
CALM = clathrin assembly lymphoid myeloid leukaemia  
CNS = central nervous system 
GPI = glycosyl-phosphatidylinositol 
GSIs = γ-secretase inhibitors  
HD = Huntington’s disease  
Htt = huntingtin gene  
IMP = intramembrane proteases  
LGMN = legumain  
MAPT = Microtubule-Associated Protein Tau  
MBD = Microtubule-binding domain  
MMP-10 = matrix metalloproteinase 10 
NES = nuclear export signal  
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ND = neurodegenerative diseases  
PICALM = phosphatidylinositol binding clathrin assembly protein  
Pen-2 = presenilin enhancer-2  
PrP
C
 = cellular prion protein  
PS = presenilin  
SPP = signal peptide peptidase  
SPPL = SPP-like proteases 
TMD = transmembrane domain  
 
 
Abstract 
Endoproteolysis is a normal post-translational process in the eukaryotic cell that had 
played a role early on in protein evolution allowing protein catabolism and the 
generation of amino acids. Endoproteolytic cleavage regulates many crucial cellular 
processes including the activity of many proteins, their protein-protein interactions 
and the amplification of cell signals. Not surprisingly, disruption or alternation of 
endoproteolytic cleavage maybe the root cause of many human diseases such as 
Alzheimer’s disease, Huntington’s disease and prion diseases. Most 
neurodegenerative diseases (ND) are caused by the build-up of misfolded proteins and 
the promotion of aggregation events. A common event that occurs in these ND is the 
alteration of endoproteolytic cleavage due to genetic mutations of the associated-
proteases or in the target substrate. Endoproteolytic cleavage resulting in protein 
truncation has significant effects on the structure and function of a protein 
representing a common feature of ND.  In this review, we will discuss the 
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endoproteolytic cleavage events that lead to ND, namely Alzheimer’s disease, 
Huntington’s disease and prion diseases. 
 
Overview of endoproteolytic cleavage 
Endoproteolytic cleavage is the break down of proteins into smaller polypeptides or 
amino acids. This process is accelerated mainly through the action of proteases. 
Under normal circumstance, proteolysis is the physiological function that provides 
nutrients to the organism it may serve as a means to control the activity of a protein 
after protein synthesis. This process is important for cellular homeostasis thus 
allowing the regulation of cellular processes as well as removing the build up of 
unwanted protein products that could be toxic to the cell. Not surprisingly, 
deregulation of endoproteolysis can result in a number of human diseases such as 
pancreatitis, diabetes mellitus, Alzheimer’s disease (AD), prion diseases, emphysema, 
muscular dystrophy, to name a few. In this review, we shall focus on the deregulation 
of proteolysis in neurodegenerative diseases, namely Alzheimer’s disease, 
Huntington’s disease (HD), and Prion diseases. 
 
Alzheimer’s disease 
Alzheimer disease (AD) is neuropathologically characterized by neuronal loss and the 
emergence of two forms of protein aggregates: senile plaques and neurofibrillary 
tangles [1]. AD is a sequential and progressive disease of the brain resulting in 
irreversible loss of neurons. The effect has a profound consequence on the affected 
individual with gradual loss of intellectual abilities especially the memory and the 
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ability to reason, thus hindering the person’s normal life activities and cognitive 
function. 
 
APP processing 
Amyloid-β protein (Aβ) is mainly found in senile plaques. Aβ is generated from its 
precursor called amyloid precursor protein (APP) via sequential cleavage by the β- 
and γ-secretases [2] (Figure 1). Notably, genetic mutations observed in patients of 
mainly the inherited form of familial AD resulted in increased production or 
aggregation of Aβ, indicating that Aβ is a seed of AD pathogenesis. Specifically, the 
C-terminal region of Aβ shows diversity and the longer Aβ peptide is principally 
deposited in AD patient brains [3]. Therefore, the γ-secretase has become a major 
molecular target in drug discovery of AD. The putative APP γ-cleavage sites related 
to amino acid residues are located at the transmembrane domain (TMD). In fact, it has 
taken more than a decade of research to advance our current understanding of the γ-
secretase, which performs endoproteolysis within the TMD [4]. Firstly, the genes to 
be identified by genetic analyses of the familial form of AD were those of the multi-
spanning membrane protein encoding called presenilin (PS) 1 and 2 [5]. Remarkably, 
the missense mutations causing disease are likely to change γ-secretase cleavage of 
APP resulting in elevated production of aggregation-prone Aβ-form (Aβ42) as 
compared with the other main Aβ species, Aβ40 [6, 7]. Secondly, the ablation of 
presenilin eliminated cleavage by the γ-secretase cleavage of APP [8, 9] and the intra-
membrane aspartates found in PS TMD-6 and TMD-7 are necessary for Aβ 
production [10]. A number of cross-linking approaches showed that γ-secretase 
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inhibitors (GSIs) directly implicated and targeted the PS proteins [11, 12]. Lastly, the 
perturbed function of the clathrin assembly lymphoid myeloid leukaemia protein gene 
(CALM) that is encoded by the phosphatidylinositol binding clathrin assembly 
protein (PICALM) was shown to cause alteration of the lysosomal localisation of the 
γ-secretase and in turn the production of Aβ42 [13, 14]. These studies demonstrate 
that PS possesses the catalytic activity resulting in γ-secretase intramembrane 
cleavage of APP, thus affecting AD pathogenesis.  
 PS is part of a family of intramembrane proteases (IMP) that are distinguished 
by the topology of their transmembrane domain and also by the nature of the 
membrane active site amino acid residues. The aspartate IMPs are located near two 
catalytic aspartate amino acid residues found in PSs, signal peptide peptidase (SPP), 
and SPP-like (SPPL) proteases [15, 16]. The catalytic aspartate of IMPs is located 
within the Gly-X-Gly-Asp motif and, hence, these proteases are known as the GXGD-
type proteases [17]. The GXGD motif is conserved in type 4 prepilin peptidase 
proteins, and is prerequisite to many bacterial protease cleavages. Interestingly, SPP 
was originally identified by a chemical biology approach and contains the same 
GXGD motif but differs according to its primary sequence and topology [18]. 
Nevertheless, the expression of PS alone is not sufficient to reconstitute the γ-
secretase activity. A number of genetic and biochemical studies have demonstrated 
that PS required three further partners, nicastrin [19], anterior pharynx-defective 1 
(Aph-1), and presenilin enhancer-2 (Pen-2) [20]. These subunits of the γ-secretase 
associate in a 1:1:1:1 stoichiometry [21] and co-expression of these binding partners 
along with PS was sufficient to reconstitute the γ-secretase activity [22, 23]. The 
activity of the γ-secretase complex is regulated by an auto-endoproteolysis cleavage 
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event of PS between the TMD-6 and TMD-7 generating N- and C-terminal fragments 
[24] that only associate with γ-secretase inhibitors or demonstrate strong proteolytic 
activity [12, 25]. The activity through this auto-endoproteolysis is regulated by an 
unknown mechanism. Our studies have defined that subunits of the 
oligosaccharyltransferase DC2 and KCP2) complex normally involved in N-
glycosylation of proteins at the ER can regulate PS endoproteolysis to promote γ-
secretase activity [26]. 
 
Tau protein and neurofibrillary tangles 
The other contributing factor to AD is the emergence of tau protein snarls found in 
neurofibrillary tangles that accumulate in AD and other dementias. Increasing 
evidence suggests that the soluble form of tau causes the most damage in 
neurodegeneration [27]. On one hand, a study has shown that tau ‘stickiness’ is 
because of its ability to aggregate that contributes to its toxicity [28].  
 
Tau truncation 
Tau protein is naturally an intrinsically disordered protein singly encoded by 
Microtubule-Associated Protein Tau (MAPT) gene located on chromosome 17q21 in 
humans [29] (Figure 2). Tau protein is mainly expressed in the axons of neurons of 
the central nervous system (CNS) and also found in lower amounts in other cell types 
in the CNS [30]. In the adult human brain, tau mRNA is spliced with or without three 
regions encoded by exon 2, exon 3 and exon 10, resulting in 6 different isoforms of 
tau [31, 32]. There is also alterative splicing of exon 10 yielding to tau isoforms 
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containing 3 (3R) or 4 (4R) imperfect MT-binding repeats in the C-terminal domain, 
both of which are found in the tangles of patient brains with tauopathy [33, 34]. The 
3R and 4R isoforms are found in equivalent amounts in the healthy adult brain [35]. 
The longest form of human tau is 441 amino acids long (Figure 2). Tau can be 
subdivided into two domains, the N-terminal projection domain and the C-terminal 
microtubule-binding domain (MBD). The N-terminal domain of tau plays an 
important role in signal transduction pathways through its interaction with proteins 
such as Phosphoinositide phospholipase C-γ (PLC-γ) and Sarcoma (Src)-kinases. The 
C-terminal domain, also known as the microtubule-binding domain (MBD), controls 
the rate of polymerization of microtubules and that is directly involved in the 
association of functional proteins such as protein phosphatase 2A (PP2A) or PS1 [36]. 
Mutations found at the gene level in MAPT linked to inherited tauopathies are mainly 
grouped into two categories: mutations that affect the protein levels or mutations 
affecting mRNA splicing, leading to elevated 4R tau production. In addition, many 
mutations found in exon 10 can effect both the protein and the RNA levels of tau [37]. 
In the eukaryotic cell, the MT cytoskeleton is an important network that plays a 
pivotal role in many cellular processes such as motility, morphogenesis, mitosis, 
meiosis, and the trafficking of organelles and macromolecules. The major constituent 
of MTs is the heterodimer of α- and β-tubulin proteins. The nature of MTs is highly 
dynamic showing a non-equilibrium behaviour often termed dynamic instability [38]. 
The MTs adopt rapid stochastic transition through growth and shortening as an effect 
of the interaction of the heterodimer of tubulin dimers at its ends. This provides a 
mechanism for Tau protein to promote tubulin polymerisation and thus stabilize MTs 
[39-41]. The functional role of tau was initially shown to promote the assembly and 
stability of MTs [39] and to associate with the cytoskeleton. Tau interacts strongly 
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with MTs [42], and after associating with the MT via the repeat regions, stabilizes the 
MTs at the plus end, thus providing stability to the MTs during growth phases, whilst 
tau N-terminal domain may act as a ‘spacer’ region between tau and the MTs 
ensuring the correct distance between them [43-46]. Also, there are a number of 
studies which implicate and corroborate that tau enhances the stabilization and 
assembly MTs on one hand, and tau mutations alter the association of tau with MTs 
on the other hand. For example, tau mutations such as G272V, DK280, P301L, 
P301S, L315R, G335V, V337M, and R406W alter tau’s ability to interact with the 
MTs affecting MT assembly with a direct affect upon the cytoskeleton and all the 
activities associated with this network [44, 47-51]. This could be due to an alteration 
in the phosphorylation status of tau that could be essential to regulate tau-MT 
interactions [52, 53], and, at the same time, to changes to the domain structure of the 
MT-binding site.  
Several cellular factors have been reported to affect tau aggregation, such as 
post-translational modifications including phosphorylation and acetylation (see 
review for further information [54, 55]), and proteolysis, including the molecular 
chaperone machinery. Tau proteolytic cleavage could play an important role in tau 
aggregation. Caspases-3 and -6 can cleave tau at amino residue sites D421 and D348 
but caspase 3 has a greater efficiency [56]. In fact, tau cleavage site at D421 has 
already been observed in AD patient brains [56-58]. Furthermore, truncation of tau at 
D421 site accelerates tau aggregation compared to tau full length form [56] and this 
could act as a seed to initiating the process of aggregation of wild-type tau, as a 
mechanism prior to tangle formation [59, 60]. Tau cleavage by caspase does not 
impede hyperphosphorylation since both tau phosphorylation and truncation 
modifications are found in the brain of AD patients [56]. Tau phosphorylation slows 
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its proteolytic processing and conversely its de-phosphorylation facilitates its 
clearance [61]. Furthermore, the D421-cleaved tau form can be phosphorylated by 
GSK3β [59].  
In addition to caspase cleavage, tau can be cleaved by other types of proteases 
including cathepsins, calpains, and thrombin [60, 62-64]. Pre-aggregated Aβ 
treatment results in tau truncation by calpain 1 generating a tau fragment 45 – 230 
amino acids (aa) [60] that is commonly found in many tauopathies [65]. This 
fragment (45-230 aa) of tau is particularly neurotoxic whilst other fragments 
generated by the calpain 2 protease are neuroprotective [60, 66] through their ability 
to form aggregates when arachodonic acid is present, thus perturbing aggregation of 
tau full length [65]. Recent studies have shown that tau could be cleaved by another 
type of protease called asparagine endopeptidase (AEP) also known as legumain 
(LGMN). AEP is a cysteine protease located in the lysosomes, which cleaves its 
substrates within the C-terminal region of the asparagine [67, 68]. The AEP protease 
is auto-activated and involves the removal of both C- and N-terminal pro-peptides at 
varying pH levels [69]. Tau protein undergoes cleavage by AEP at positions N255 
and N368 [70]. This cleavage gives rise to several fragments that are unable to bind to 
MTs but can efficiently aggregate through the exposure of aggregation-prone tau 
residues i.e. 275-280 and 306-311 [70]. These tau AEP-cleaved fragments are readily 
hyperphosphorylated [70]. Altogether, these studies demonstrate that tau can be 
cleaved by many proteases and the fragments generated may promote aggregation and 
toxicity, thus contributing to the pathological events in AD.  
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Huntington’s disease (HD) 
Huntington’s disease (HD) is a progressive inherited neurodegenerative disease which 
results in motor, cognitive and psychiatric symptoms [71]. HD is triggered by the 
expansion of the CAG repeat on chromosome 4 that encodes glutamine in the N-
terminal of huntingtin (Htt) [72]. The normal Htt gene has less than 36 CAG repeats 
whilst the abnormal Htt gene has more than 36 CAG repeats. For HD, the disease 
starts in the striatum in medium-spiny neurons and later penetrates deep into the 
cortex [71]. Htt protein is widely expressed in the CNS and in other non-neuronal 
tissues [73] and dispersed throughout the intracellular compartments [74-76]. The 
human Htt protein is a large protein with a molecular weight of 350 kDa and with 
3144 aa. It is made up of several domains including the HEAT (Htt, elongation factor 
3, the PR65/A subunit of protein phosphatase 2A and the lipid kinase Tor) domains 
that are 50 aa in length and consist of 2 anti-parallel α-helices that form a hairpin that 
is important for protein–protein interactions (Fig. 3). Approximately, 16 HEAT repeat 
domains have been found in Htt gene, which are arranged into clusters of 4 [77, 78]. 
The role and function of the HEAT domains for Htt is unknown. In addition, Htt 
contains 4 PEST sequences where the name is derived from P (proline), E (glutamic 
acid), S (serine) and T (threonine) serving as signals for protein degradation by the 
proteasome [79]. 
Htt interacts with a number of proteins that play a role in apoptosis, vesicle transport, 
endocytosis, morphogenesis, cell signalling and transcriptional regulation. The 
function of Htt is believed to act as a scaffolding protein i.e. a bridge bringing its 
interacting partners in close proximity to allow signals to be transferred [80]. 
Interestingly, Htt has been shown to elevate the production of brain-derived 
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neurotrophic factor (BDNF), a growth factor produced by striatal neurons [81]. 
 
Proteolysis in Huntington’s disease (HD) 
Htt protein is proteolytically cleaved at many sites generating several N-terminal 
fragments. Htt can be cleaved by several proteases including calpain, caspases, AEPs 
and matrix metalloproteases. Htt contains 2 calpain sites located at positions 469 and 
536 aa [82, 83] (Figure 3). Htt can be cleaved by several caspases such as caspase 3 at 
positions 513 and 552 aa [84, 85], caspase 2 at 552 aa [86] and by caspase 6 at 586 aa 
[85]. The matrix metalloproteinase MMP-10 cleaves the Htt protein at 402 aa and is 
active in mice with HD [87]. The presence of the Htt fragments, where the cleavage 
sites have been mutated, promote lower toxicity of Htt indicating that proteolytic 
processing of Htt could contribute to HD pathogenesis [84, 88, 89]. Hence the 
proteolytic processing of Htt resulting in the generation of N-terminal fragments that 
contain polyglutamine tract could be a necessary stage in HD progression. This is due 
to N-terminal fragments which are more prone to aggregation and promote toxicity. 
These N-terminal fragments have been demonstrated to be present both in the mouse 
HD models and in the brains of HD human patients [83, 90, 91]. HD progression in 
HD mouse model have shown to be perturbed through the development of protease 
inhibitors or by mutating specific sequences important in Htt protease cleavage [85, 
88]. However, the task to prevent all the proteolytic cleavages of Htt is difficult 
through the use of protease inhibitors and represents a therapeutic challenge for drug 
discovery. Future efforts should be targeted to identify the specific roles of proteases 
and the effects of N-terminal truncated fragments of Htt on HD progression and their 
implications in the pathological process. 
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Prion diseases 
Prion diseases such as Creutzfeldt-Jakob disease in humans, scrapie in sheep and 
bovine spongiform encephalopathy in cattle, are all infectious and potentially fatal 
neurological conditions as a result of misfolding of cellular prion protein (PrP
C
) 
converted into a structurally different β-sheet-rich pathogenic isoform (PrP
Sc
) that is 
partially resistant to proteinase-K treatment and tend to aggregate [92]. The PrP
C
 has 
a bipartite structure, N-terminal domain is disordered whilst the C-terminal domain is 
more structured containing 3 α-helices and 2 β-strands [93]. The function of PrPC is 
not clear but most studies indicate that PrP
C 
could provide neuroprotection and it is a 
neurotrophic protein [94]. Neuroprotective function of PrP
C
 has been demonstrated in 
many in vitro and in vivo studies [95, 96]. These studies showed that the expression of 
PrP
C
 was sufficient to slow down cell death and, in several other expression studies, 
PrP
C
 was shown to prevent cell death in stress conditions of serum deprivation of 
neurons [97]. Follow up studies have provided much evidence for PrP
C
 implication in 
cellular survival as well as regulation of cell growth, proliferation, differentiation and 
stem cell expansion [98, 99]. 
 
Proteolysis in Prion diseases 
PrP
C
 associates with the plasma membrane through a glycosyl-phosphatidylinositol 
(GPI) anchor. Early on after translocation into the endoplasmic reticulum, the N-
terminal signal peptide is removed by signal peptidase followed by cleavage of the C-
terminal hydrophobic domain (residues 231-253) before the attachment of a GPI 
anchor to the C-terminus. PrP
C
 undergoes at least three proteolytic cleavage events 
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after trafficking through the secretory pathway to the plasma membrane [100]. At the 
plasma membrane or in the endosomes, PrP
C
 can be cleaved by α-cleavage at position 
110-111 and 112 aa to yield two products: (i) PrP
C1
, a product of 17kDa containing 
the GPI-anchor C-terminal fragment, and (ii) a 11kDa N-terminal fragment that is 
released from the cell into the extracellular space (Figure 4). α-cleavage was first 
shown for the chicken PrP [101] and then in later studies shown in samples from 
humans [102]. The protease responsible for the α-cleavage of PrPC is still unknown 
but is currently known as the α-PrPase [103]. However, the ADAM (A Disintegrin 
And Metalloprotease) family could be involved in the α-cleavage of PrP. ADAM10 
and ADAM17 (also known as TACE) are implicated [104] in the α-cleavage of PrP. 
Also, ADAM9 [105] and ADAM8 [106] found in muscle could also be involved in α-
cleavage [107]. There still remains some controversy as to which protease is directly 
involved and how this process is regulated [107]. It is thought that the cleavage event 
occurs in the endosome [108] or the late endocytic pathway [109]. α-cleavage occurs 
in normal brains with approximately 50% of C1 present compared to full length PrP 
[102]. PrP
C
 can also undergo β-cleavage by a calpain protease at position 89-90 aa to 
produce PrP
C2
, a 20kDa fragment containing the GPI-anchor and also a smaller 8kDa 
fragment known as PrPN2. β-cleavage of PrPC is a pathological event occurring at the 
plasma membrane in prion diseases which is promoted during conditions of oxidative 
stress such as the presence of reactive oxygen species. Also, some of PrP
C
 is shed 
constitutively at the plasma membrane by the zinc metalloprotease called ADAM10 
[100]. Most evidence indicates that α-cleavage of PrP has a neuroprotective function 
as opposed to contributing to prion diseases. In contrast, β-cleavage generates the 
PrP
C2
 fragment that is sufficient to support prion disease and appears to be abundant 
in the brains of prion-diseased individuals than in healthy ones [102], indicating that 
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β-cleavage could contribute to prion diseases. However, it is likely that both types of 
cleavage have a role in prion disease but α-cleavage prevents PrP from converting 
into PrPSc. 
Concluding remarks 
Human NDs such as AD, HD and prion diseases are characterized by 
neurodegeneration that leads to a progressive functional decline. More than 20 million 
people worldwide are suffering from ND each year. The number of individuals with 
NDs is increasing rapidly due to lack of effective therapies. Thus, novel efficient 
therapy for ND is foremost unmet health need. NDs such as AD, HD and prion 
diseases greatly differ in respect of their clinical manifestation, duration, onset, etc. 
Altogether, these human diseases share numerous common features such as altered 
protein cleavage, protein aggregation, oxidative stress, etc. The major pathological 
event that is crucial and shared by many NDs such as AD, HD and prion diseases is 
proteolytic cleavage of disease-modifying proteins. Emerging current evidence 
suggests that protein truncation not only acts as the driving force behind ND but also 
serves as a seed for regeneration of novel truncated forms that finally speed up the 
aggregation process leading to oligomeric assemblies of Htt and PrP, amyloid plaque, 
and neurofibrillary tangles formation. To this end, we need to concentrate our efforts 
towards understanding the endoproteolytic processes and how to perturb these 
proteases without affecting cellular homeostasis. 
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Figure legends 
Table 1:  List of endoproteases in ND 
Table showing the substrates and their endoproteases associated with human 
neurodegeneration. 
 
Figure 1:  APP processing 
(A) Schematic representation showing the domains of amyloid precursor protein 
(APP) and sites of endoproteolytic cleavage. (B) The amyloid precursor protein 
(APP) processing pathways. The APP protein transmembrane can be processed via 
two pathways: the non-amyloidogenic α-secretase pathway (no plaque formation) or 
the amyloidogenic β-secretase pathway (plaque formation). The non-amyloidogenic 
pathway results in the α-secretase cleaving β-amyloid (Aβ) in the centre to release a 
soluble fragment of APP called sAPP-α. Following this cleavage, the APP C-terminal 
fragment 83 (APP-CTF83) is cleaved further by the γ-secretase to release two 
fragments, the APP intracellular domain (AICD) and the P3 fragment. The 
amyloidogenic pathway results in the β-secretase cleaving APP to generate a soluble 
fragment called the sAPP-β. The CTFβ is then cleaved by the γ-secretase to generate 
Aβ40, Aβ42 and AICD. 
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Figure 2:  Tau truncation 
Schematic representation of functional domains of the longest tau isoform (441 amino 
acids). Tau protein can be divided into two domains: the N-terminal projection 
domain, including an acidic and a proline-rich region and a C-terminal microtubule 
binding domain (MBD). The MBD contains three or four repeats (R1-R4) with a 
flanking N-terminal proline-rich region extending into the projection domain that 
contains most of the Ser/Thr-Pro motifs.  The endoproteolytic cleavage sites are 
indicated. 
 
Figure 3:  Htt cleavage sites 
Schematic representation of the Htt protein. The full-length Htt protein consist of 
3,144 amino acids, with a molecular weight of 350 kDa. The N-terminal region 
contains 17 amino acids (N17) comprising of many post-translational modifications 
including sites for phosphorylation and ubiquitination. Immediately after the N17 
region are the polyglutamine (polyQ) and polyproline (polyP) regions. The region 
between 400 to 600 amino acids contains many endoproteolytic sites for proteases 
such as caspases 2, 3, 6, calpain, and matrix metalloproteinase 10 (MMP-10). 
Approximately, 16 HEAT repeats have been identified in Htt with unknown function. 
The C-terminal region consists of a leucine-rich nuclear export signal (NES), which 
could target the full-length Htt to the cytoplasm.  
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Figure 4:  PrP cleavage sites 
Schematic representation of the prion protein. The N-terminus is structurally 
disordered containing a signal peptide and an octameric repeat region. The 
C-terminus is structurally ordered consisting of three α-helixes, two β-strands, and a 
disulfide bond (-S-S-). A glycosylphosphatidylinositol (GPI) anchor that anchors the 
prion protein at the cell surface is found at the C-terminus. The endoproteolytic 
cleavage sites are indicated. 
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